Prevencio

About Prevencio

Prevencio, headquartered in Kirkland, Washington, is a life science and biotech company focused on revolutionizing blood tests for cardiovascular health. The company leverages advanced artificial intelligence (AI) to develop its HART tests, which are designed to provide highly accurate diagnostics for cardiovascular disease (CVD). These tests aim to improve patient outcomes and reduce healthcare costs by enabling early detection and better management of heart conditions.

Prevencio primarily serves healthcare providers, including hospitals, clinics, and specialized cardiology centers. The company operates in the healthcare and biotechnology market, targeting the growing need for advanced diagnostic tools in cardiovascular care. Its business model revolves around the development, marketing, and sale of its proprietary HART tests. Revenue is generated through the sale of these tests to healthcare institutions and through partnerships with other medical technology companies.

The company's innovative approach combines multiple biomarkers with machine learning algorithms to enhance the accuracy of CVD diagnosis and prognosis. This method surpasses traditional single biomarker tests, offering a more comprehensive assessment of heart health. Prevencio's commitment to scientific excellence and patient care has earned it several accolades, including the Top Heart Care Solution, Top Heart Award, and Top Med Tech Award.